For noninfectious diarrhea in adults living with HIV/AIDS who are on ART*
The efficacy of Mytesi 125-mg delayed-release tablets twice daily was evaluated in a randomized, double-blind, placebo-controlled (one month) and placebo-free (five month), multi-center study (the ADVENT trial). The study enrolled HIV-positive patients on stable ART with a history of diarrhea for 1 month or more.
A significantly larger proportion of patients in the Mytesi 125-mg twice daily group experienced clinical response compared with patients in the placebo group (p < 0.01).
†Baseline watery stools per week is the average of the combined treatment groups for patients on placebo (n=138) and patients on Mytesi 125-mg twice daily (n=134).
Source: MacArthur, et al. HIV Clinical Trials 2013; 14(6): 261-273